Platelet Transfusions in Critically Ill Patient (RE-CCIP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03325140|
Recruitment Status : Recruiting
First Posted : October 30, 2017
Last Update Posted : January 18, 2019
Between 10 and 15% of critically ill patients require platelet transfusion within their intensive care unit (ICU).
Platelets (PLT) are given to prevent bleeding in thrombocytopenic patients or to treat bleeding as part of massive transfusion or in bleeding thrombocytopenic patients.
International and local guidelines (American Association of Blood Banks-AABB) are mainly based on experts' opinion. The efficacy of PLT transfusion in the ICU setting remains poorly studied and unknown and the administration of PLT may be associated with adverse effects including an increased risk of hospital acquired infection. Finally, the short PLT shelve-life may be responsible for inventory issues. Altogether, this makes very important to improve the evidence that support PLT transfusion in ICU patients.
This is a multicentre prospective observational study that aims to first determine PLT transfusion efficacy and to identify the parameters associated with transfusion efficacy and to analyse the compliance with international (and local) guidelines of PLT transfusion in ICU patients.
|Condition or disease|
|Platelet Transfusion Critical Illness|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Platelet Transfusion Efficacy in Critically Ill Patients|
|Actual Study Start Date :||May 30, 2018|
|Estimated Primary Completion Date :||December 15, 2019|
|Estimated Study Completion Date :||December 15, 2019|
- platelet transfusion efficacy [ Time Frame: between 18 hours and 28 days after transfusion ]corrected count platelet increment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03325140
|Contact: AUBRON Cécile||+33 2 98 34 78 email@example.com|
|Angers, France, 49100|
|Contact: Pierre ASFAR, Pr firstname.lastname@example.org|
|CHRU de Brest||Recruiting|
|Brest, France, 29609|
|Contact: Aubron Cécile email@example.com|
|Sub-Investigator: Olivier Huet, Pr|
|CH des Pays de Morlaix||Recruiting|
|Morlaix, France, 29 672|
|Contact: Pierre-Yves EGRETEAU 02 98 62 61 60 firstname.lastname@example.org|
|CHU de Nantes||Recruiting|
|Nantes, France, 44093|
|Contact: LE MEUR Anthony email@example.com|
|CHU de Rennes||Recruiting|
|Rennes, France, 35033|
|Contact: SEGUIN Philippe firstname.lastname@example.org|
|Sub-Investigator: TADIE Jean-Marc|
|CHU de Tours||Recruiting|
|Tours, France, 37044|
|Contact: EHRMANN Stephan email@example.com|